Key players in angioedema treatment market include Shire plc, CSL Limited, Pharming Group NV, Ionis Pharmaceuticals, Inc., iBio Inc., and BioCryst Pharmaceuticals, Inc. In 2017, Shire plc. received European Commission (EC) approval for label extension, that increases indication for FIRAZYR (icatibant injection), broadening use to adolescents and children aged 2 years and older, with HAE caused by C1-esterase-inhibitor (C1-INH) deficiency.
Angioedema Treatment Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients